Avelios Wins Fresenius to Build an AI-Native Digital Health Ecosystem

News Article

Fresenius —  Europe’s largest private hospital operator — is investing in our portfolio company Avelios Medical and with it in the build-out of an open, interoperable, and AI-native digital health ecosystem for Europe. 

Fresenius joins the technology partnership between Avelios and SAP, which was closed earlier this year, bringing its extensive experience from real-world clinical practice. At the center stands the Avelios Hospital Information System (HIS) as the core platform for a modern, integrated care infrastructure, built on a new generation of clinical architecture and a structured data model that enables AI-native care and sovereign data use. 

Avelios is solving a real problem at exactly the right moment. The clinical IT market is undergoing a fundamental shift, and hospitals need orientation. Having SAP and Fresenius, two of Europe’s most influential players, validate the team’s approach is a strong signal: for the platform, the product, and an outstanding founding team we have been backing since their pre-seed round in 2021. 

Founding team of Avelios Medical (Photo: Avelios Medical) 

Do you want to

learn more?

Zum Artikel

Daniela Bach Principal

Daniela BachPrincipal

I am your contact

for all press inquiries:
Tobias Jacob

More News

Last update 14 hours ago
zum Artikel

News

1 July 2026

Axel Nitsch and Johannes Weber Named Partners at HTGF – Doubling Down on AI and Deep Tech

zum Artikel

News

23 June 2026

JUPUS Raises 13 Million Euros in Series A

zum Artikel

News

17 June 2026

Seqana raises EUR 3.2M, led by Pymwymic, to extend soil health measurement beyond carbon

zum Artikel

News

15 June 2026

A radically new biological approach for cancer patients: CollimateHealth targets immune responses through microbeam radiation therapy – €6 million seed round oversubscribed

zum Artikel

News

8 June 2026

Qnami Joins Quantum Design to Accelerate the Future of Quantum Sensing

zum Artikel

News

1 June 2026

T-CURX acquires Pantherna Therapeutics to accelerate clinical translation of its non-viral in vivo CAR-T strategies